Laser TreatmentNCT07442422
Endocare Repair Efficacy Skincare Products in the Use of Post-laser Treatment
A study testing Active product contained 40% secretion of SCA in people with Laser Treatment, run by Huashan Hospital at 1 site in China.
Trial summary
To Evaluate the Efficacy and Safety of Endocare Repair Efficacy Skincare Products in the Repair of Facial Skin Following Ablative Fractional Laser Treatment. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Laser Treatment
- What is being tested?
- Active product contained 40% secretion of SCA
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 1 siteChina
- Study dates
- 14 Apr 2023to 30 Jun 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Individuals aged 30-65 years;
- Candidates for ablative fractional laser treatment on the face;
- Agree to undergo photographic documentation before and after the ablative fractional laser procedure and during follow-up visits;
- Refrain from using other similar products (except facial cleansers) after ablative fractional laser treatment;
- Written informed consent obtained.
Who cannot join
- known hypersensitivity to product ingredients;
- active skin infections;
- history of keloid formation;
- immunosuppressive therapy and pregnancy or lactation.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Single-center, Prospective, Randomized, Double-blind, Self-controlled Clinical Study Evaluating the Efficacy and Safety of Endocare Repairing Skincare Product in Skin Recovery After Ablative Fractional Laser Treatment .
To Evaluate the Efficacy and Safety of Endocare Repair Efficacy Skincare Products in the Repair of Facial Skin Following Ablative Fractional Laser Treatment.
Read the detailed description
A single-center, prospective, randomized, double-blind, split-face (hemifacial) self-controlled clinical trial was conducted with 24 participants aged 21-37 years who underwent fractional CO2 laser treatment on both sides of the face. A skincare product containing SCA was applied to one side, and a placebo moisturizer was applied to the other side. Evaluations were conducted immediately after treatment and on days 1, 3, 5, 7, 14, and 28 post-treatment. The primary outcome was the evaluation of microcolumn density under dermoscopy. Secondary outcomes included transepidermal water loss (TEWL), melanin index (MI), erythema index (EI), investigator global assessment (IGA), patient global assessment(PGA), and visual analog scale (VAS) for pain. Safety was evaluated by monitoring adverse events.
- Conditions
- Laser Treatment
- Being tested
- Active product contained 40% secretion of SCA, Identical-appearing placebo cream
- Keywords
- Ablative Fractional Laser Treatment, Repair of Facial Skin, Endocare
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active product contained 40% secretion of SCACombination product
One half of the face received the active product contained 40% secretion of SCA covering all lasered areas.
Identical-appearing placebo creamCombination product
The other half received an identical-appearing placebo cream (a basic moisturizer containing no SCA ingredients, but otherwise matching the active product in appearance and texture), covering all lasered areas.
| Study group | Role | What they receive |
|---|---|---|
| SCA Side | Active comparator | One half of the face received the active product contained 40% secretion of SCA Receives: Combination Product: Active product contained 40% secretion of SCA |
| Placebo Side | Placebo comparator | The other half received an identical-appearing placebo cream (a basic moisturizer containing no SCA ingredients Receives: Combination Product: Identical-appearing placebo cream |
What is being measured
The primary outcome is the main question the study is designed to answer.
Microcolumn Density Under Dermoscopy
The primary outcome was the rate of re-epithelialization, assessed by the density of visible microcolumns which was examined using the Medicam®1000 dermoscopy system. This measure was complemented by a clinical healing score (0-3 scale for each side, where 0 = fully healed skin, 1 = fine pinpoint scaling, 2 = visible micro-crusts, 3 = obvious unhealed areas) assigned by a blinded dermatologist.
Measured: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
Secondary outcomes (6)
Transepidermal Water Loss (TEWL)
Measured: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
Melanin Index (MI)
MI can detect pigment changes, allowing assessment of any PIH or other dyschromia resulting from the laser or differential healing. Higher MI indicates a prolonged post-laser reaction.
Measured: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
Erythema Index (EI)
EI quantifies redness to track the resolution of laser-induced erythema. Higher EI indicates a prolonged post-laser reaction.
Measured: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
Investigator Global Assessment (IGA)
Key symptoms including erythema, edema, crusting, exudation and crusting were graded (with a score from 0-3) by the investigator at each visits.
Erythema:
0 - No redness
- - Light red or pink
- - Moderate redness
- - Bright red
Edema:
0 - No edema
- - Mild edema
- - Moderate edema
- - Severe diffuse edema
Exudation:
0 - No exudation
- - Mild exudation
- - Moderate exudation
- - Diffuse exudation
Crusting:
0 - No crusting
- - Thin crust
- - Moderately thick crust
- - Thick crust adherent to skin
Measured: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
Patient Self-Assessments (PGA)
Patients rated tightness and burning in a scale of 0-3. 0=none, 1=mild, 2=moderate, 3=severe.
Measured: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
Visual Analog Scale (VAS)
Assessed immediately after treatment and at follow-up visits using a 0-10 VAS score. 10 being the highest pain.
Measured: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2026
- Study start14 Apr 2023
- Primary completion30 Jun 2023
- Study completion30 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Laser TreatmentStudies of the same condition, open and under way.
- More trials run by Huashan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- 24 participants underwent fractional CO2 laser treatment on both sides of the face. A skincare product containing SCA was applied to one side, and a placebo moisturizer was applied to the other side.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Huashan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yanjun Dan, Huashan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07442422
- Sponsor's protocol ID
- 2022-554
- Status last verified
- Feb 2026
- First submitted
- 19 Feb 2026
- Last updated
- 2 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared because this single-center study does not have a formal data sharing infrastructure, and participants did not provide consent for public data sharing. Aggregated results may be reported in publications or upon reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-center, Prospective, Randomized, Double-blind, Self-controlled Clinical Study Evaluating the Efficacy and Safety of Endocare Repairing Skincare Product in Skin Recovery After Ablative Fractional Laser Treatment .
- ClinicalTrials.gov ID
- NCT07442422
- Acronym / sponsor ID
- 2022-554
- Conditions
- Laser Treatment
- Keywords
- Ablative Fractional Laser Treatment, Repair of Facial Skin, Endocare
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Huashan HospitalUniversity, hospital or other
- Study start
- 14 Apr 2023 (actual)
- Primary completion
- 30 Jun 2023 (actual)
- Study completion
- 30 Jun 2023 (actual)
- First posted
- 2 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To Evaluate the Efficacy and Safety of Endocare Repair Efficacy Skincare Products in the Repair of Facial Skin Following Ablative Fractional Laser Treatment.
Detailed description
A single-center, prospective, randomized, double-blind, split-face (hemifacial) self-controlled clinical trial was conducted with 24 participants aged 21-37 years who underwent fractional CO2 laser treatment on both sides of the face. A skincare product containing SCA was applied to one side, and a placebo moisturizer was applied to the other side. Evaluations were conducted immediately after treatment and on days 1, 3, 5, 7, 14, and 28 post-treatment. The primary outcome was the evaluation of microcolumn density under dermoscopy. Secondary outcomes included transepidermal water loss (TEWL), melanin index (MI), erythema index (EI), investigator global assessment (IGA), patient global assessment(PGA), and visual analog scale (VAS) for pain. Safety was evaluated by monitoring adverse events.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- 24 participants underwent fractional CO2 laser treatment on both sides of the face. A skincare product containing SCA was applied to one side, and a placebo moisturizer was applied to the other side.
| Arm | Type | Receives |
|---|---|---|
| SCA Side | Active comparator | Combination Product: Active product contained 40% secretion of SCAOne half of the face received the active product contained 40% secretion of SCA |
| Placebo Side | Placebo comparator | Combination Product: Identical-appearing placebo creamThe other half received an identical-appearing placebo cream (a basic moisturizer containing no SCA ingredients |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Individuals aged 30-65 years;
- Candidates for ablative fractional laser treatment on the face;
- Agree to undergo photographic documentation before and after the ablative fractional laser procedure and during follow-up visits;
- Refrain from using other similar products (except facial cleansers) after ablative fractional laser treatment;
- Written informed consent obtained.
Key exclusion criteria (4 listed)
- known hypersensitivity to product ingredients;
- active skin infections;
- history of keloid formation;
- immunosuppressive therapy and pregnancy or lactation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active product contained 40% secretion of SCAOne half of the face received the active product contained 40% secretion of SCA covering all lasered areas. | Combination product | SCA Side |
| Identical-appearing placebo creamThe other half received an identical-appearing placebo cream (a basic moisturizer containing no SCA ingredients, but otherwise matching the active product in appearance and texture), covering all lasered areas. | Combination product | Placebo Side |
Primary outcome
Microcolumn Density Under Dermoscopy
Time frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
The primary outcome was the rate of re-epithelialization, assessed by the density of visible microcolumns which was examined using the Medicam®1000 dermoscopy system. This measure was complemented by a clinical healing score (0-3 scale for each side, where 0 = fully healed skin, 1 = fine pinpoint scaling, 2 = visible micro-crusts, 3 = obvious unhealed areas) assigned by a blinded dermatologist.
6 secondary outcomes
Transepidermal Water Loss (TEWL)
Time frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
Melanin Index (MI)
Time frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
Erythema Index (EI)
Time frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
Investigator Global Assessment (IGA)
Time frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28
Patient Self-Assessments (PGA)
Time frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
Visual Analog Scale (VAS)
Time frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared because this single-center study does not have a formal data sharing infrastructure, and participants did not provide consent for public data sharing. Aggregated results may be reported in publications or upon reasonable request.
Related trials for Laser Treatment
RecruitingPhase 4
Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias
Telangiectasias, Reticular Veins
Not yet recruiting
Recurrent Aphthous Stomatitis Management in Children Using Diode Laser 980 Nanometer Versus Hyaluronic Acid Gel (RCT)
Apthous Ulcer
Not yet recruiting
The Effectiveness of High-intensity Laser Therapy in Femoroacetabular Impingement Syndrome
Femoroacetabular Impingement Syndrome, Femoro-acetabular Impingement
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Not yet recruitingPhase 1
Nanopulse Laser Therapy
TBI (Traumatic Brain Injury)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active product contained 40% secretion of SCA in people with Laser Treatment, run by Huashan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Microcolumn Density Under Dermoscopy (time frame: Day 0 (before laser, immediately after laser and after applying product) and on post-laser days 1, 3, 5, 7, 14, and 28). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.